Total Payments
$433,364
2021 Payments
$5,566
Companies
4
Transactions
472
Medicare Patients
379
Medicare Billing
$35,871
Payment Breakdown by Category
Other$380,410 (87.8%)
Travel$26,912 (6.2%)
Consulting$15,140 (3.5%)
Food & Beverage$10,864 (2.5%)
Education$38.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $380,410 | 137 | 87.8% |
| Travel and Lodging | $26,912 | 159 | 6.2% |
| Consulting Fee | $15,140 | 7 | 3.5% |
| Food and Beverage | $10,864 | 165 | 2.5% |
| Education | $38.42 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $221,502 | 204 | $0 (2021) |
| Gilead Sciences, Inc. | $174,847 | 220 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $31,911 | 35 | $0 (2018) |
| ViiV Healthcare Company | $5,104 | 13 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $5,566 | 7 | AbbVie Inc. ($5,096) |
| 2020 | $31,511 | 31 | AbbVie Inc. ($19,741) |
| 2019 | $130,046 | 142 | AbbVie, Inc. ($74,481) |
| 2018 | $135,798 | 135 | AbbVie, Inc. ($81,403) |
| 2017 | $130,442 | 157 | Gilead Sciences Inc ($60,983) |
All Payment Transactions
472 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/16/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $59.12 | General |
| Category: HIV | ||||||
| 04/22/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.55 | General |
| 03/16/2021 | AbbVie Inc. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $79.52 | General |
| Category: VIROLOGY | ||||||
| 03/15/2021 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HCV | ||||||
| 03/08/2021 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: VIROLOGY | ||||||
| 03/02/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: VIROLOGY | ||||||
| 01/25/2021 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: VIROLOGY | ||||||
| 12/23/2020 | AbbVie Inc. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $92.00 | General |
| Category: VIROLOGY | ||||||
| 12/22/2020 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: VIROLOGY | ||||||
| 12/15/2020 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: VIROLOGY | ||||||
| 12/14/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HCV | ||||||
| 12/09/2020 | AbbVie Inc. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $87.40 | General |
| Category: VIROLOGY | ||||||
| 12/08/2020 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: VIROLOGY | ||||||
| 12/07/2020 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: VIROLOGY | ||||||
| 10/20/2020 | AbbVie Inc. | MAVYRET (Drug) | Travel and Lodging | In-kind items and services | $104.65 | General |
| Category: VIROLOGY | ||||||
| 10/19/2020 | AbbVie Inc. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: VIROLOGY | ||||||
| 10/14/2020 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: VIROLOGY | ||||||
| 09/15/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HCV | ||||||
| 06/16/2020 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: HIV | ||||||
| 05/01/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $61.49 | General |
| Category: HCV | ||||||
| 05/01/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HCV | ||||||
| 04/29/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HCV | ||||||
| 03/07/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $893.00 | General |
| Category: HCV | ||||||
| 03/07/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $696.68 | General |
| Category: HCV | ||||||
| 03/07/2020 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $250.00 | General |
| Category: HCV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 14 | 379 | 8,075 | $169,443 | $35,871 |
Total Patients
379
Total Services
8,075
Medicare Billing
$35,871
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 70 | 186 | $46,314 | $10,097 | 21.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 89 | 158 | $30,178 | $8,305 | 27.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 44 | 94 | $28,482 | $5,129 | 18.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 32 | 32 | $16,640 | $3,367 | 20.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $7,062 | $1,695 | 24.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 21 | $7,161 | $1,632 | 22.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $4,730 | $1,374 | 29.0% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2020 | 11 | 7,000 | $13,363 | $1,211 | 9.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 14 | $3,934 | $1,167 | 29.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 13 | 17 | $3,264 | $991.84 | 30.4% |
| 96374 | Injection of drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 11 | 13 | $2,704 | $366.86 | 13.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2020 | 15 | 441 | $1,974 | $198.82 | 10.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 16 | 23 | $1,909 | $176.79 | 9.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 27 | 54 | $1,728 | $160.74 | 9.3% |
About Dr. James Levin, MD
Dr. James Levin, MD is a Infectious Disease healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164469466.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Levin, MD has received a total of $433,364 in payments from pharmaceutical and medical device companies, with $5,566 received in 2021. These payments were reported across 472 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($380,410).
As a Medicare-enrolled provider, Levin has provided services to 379 Medicare beneficiaries, totaling 8,075 services with total Medicare billing of $35,871. Data is available for 1 year (2020–2020), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Madison, WI
- Active Since 06/02/2006
- Last Updated 12/08/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1164469466
Products in Payments
- Mavyret (Drug) $156,123
- Epclusa (Drug) $132,153
- Viekira (Drug) $36,735
- ZEPATIER (Drug) $26,787
- MAVYRET (Drug) $24,837
- Vosevi (Drug) $4,640
- CABENUVA (Drug) $4,448
- Biktarvy (Drug) $1,060
- DOVATO (Drug) $125.11
- ISENTRESS (Drug) $46.83
- TIVICAY (Drug) $31.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Madison
Shravan Kethireddy, M.d, M.D
Infectious Disease — Payments: $50,632
Infectious Disease $50,632
David Andes, Md, MD
Infectious Disease — Payments: $43,741
Infectious Disease $43,741
Nasia Safdar, Md, MD
Infectious Disease — Payments: $22,201
Infectious Disease $22,201
Barry Fox, Md, MD
Infectious Disease — Payments: $1,096
Infectious Disease $1,096
John Cherian, Md, MD
Infectious Disease — Payments: $258.74
Infectious Disease $258.74
Dr. Amanda Carlson, M.d, M.D
Infectious Disease — Payments: $146.49
Infectious Disease $146.49